Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R. 525, Strengthening the Health Care Fraud Prevention Task Force Act (Walden) - codification of Healthcare Fraud Prevention Partnership
H.R. 506, Hospital Competition Act (Banks) - hospital consolidation
H.R. 861, End Surprise Billing Act (Doggett) - surprise medical bills
H.R. 1409. Transparency in All Health Care Pricing Act (Perlmutter) - transparency in health care pricing
H.R. 2062, Overdose Prevention and Patient Safety Act (Blumenauer) - confidential sharing of substance use disorder information
S. 1012, The Protecting Jessica Grubbs Legacy Act (Capito) - confidential sharing of substance use disorder information

Regulatory Issues:
HIPAA administrative simplification issues, including standards for privacy, security, and electronic transactions and code sets (including ICD-10), identifiers including the health plan identifier, enforcement; cybersecurity; FEHBP enrollment data clearinghouse initiative, the enrollment reconciliation process, and a related OPM reimbursement factor for records that cannot be reconciled; issues relating to health insurance plan participation in FEHBP, including contract requirements; issues relating to similarly sized subscriber group (SSSG) and MLR requirements under the FEHBP; implementation of the health savings account provisions of the Medicare Act; issues related to Medicare Secondary Payer requirements; issues related to implementation of the National Health Information Infrastructure; electronic health records, personal health records, and similar technologies; issues relating to market consolidation; issues related to hospital consolidation; issues relating to quality improvement; issues relating to the national health data stewardship; issues relating to hospital outpatient measurement and reporting; prescription drug pricing; issues related to the collection of race and ethnicity data; issues related to medical loss ratios; reference pricing; review of rates for reasonableness; preexisting condition insurance plans; issues relating to antitrust; issues relating to surprise medical bills; accountable care organizations; provider non-discrimination; coverage of preventive services; contraceptive coverage; pre-existing condition exclusions; lifetime and annual dollar limits on benefits; patient protections; grandfathered health plan provisions; issues relating to the annual fee on health insurance providers; health plan automatic enrollment requirements; issues related to qualified health plans including certification and rate filing templates; health insurance market rules; reinsurance, risk corridors, and risk adjustment; dependent coverage; summary of benefits and coverage disclosures; benefit and payment parameters; essential health benefits, actuarial value, and accreditation; NQF reauthorization; issues related to fraud, waste, abuse, Stark/Anti-Kickback laws and regulations; issues related to supplemental products; issues related to HIPAA excepted benefits; issues related to short term limited duration products; issues related to the federally-facilitated marketplaces (i.e., Exchanges/formerly referred to as the web portal); issues related to business continuity in relation to pandemics or natural events (e.g., hurricane, tornado, etc.); issues related to association health plans; issues related to cost-sharing reductions (CSRs); issues related to the refundable credit for coverage under a qualified health plan; issues related to small employer group size; issues related to Certificate of Public Advantage; issues relating to veterans health care; issues relating to family caregivers; and other issues relating to health care reform implementation.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Labor - Dept of (DOL), Treasury - Dept of, White House Office, Council of Economic Advisers (CEA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act (Klobuchar) - Part D price negotiations
S. 99, Medicare Drug Price Negotiation Act (Sanders) - Part D price negotiations, formulary changes
S. 205, Right Rebate Act (Wyden) - Medicaid drug rebate program
S. 317, ACE Kids Act (Grassley) - health homes for children with medically complex conditions
S. 377, Medicare Negotiation and Competitive Licensing Act (Brown) - Part D price negotiation
S. 470, Medicare at 50 Act (Stabenow) - Medicare buy-in option
S. 475, RxCAP Act (Wyden) - Part D cost-sharing
S. 489, State Public Option Act (Schatz) - Medicaid buy-in option
S. 516, Prescription Drug Monitoring Act (Klobuchar) - required use of PDMPs
S. 548, EMPOWER Care Act (Portman) - MFP demonstration
S. 640, Phair Pricing Act (Kennedy) -- Part D rebates at the point of sale
S. 691, Medicare Extra Rx HELP Act (Casey) - Part D assistance for low-income seniors
S. 709, Prescription Drug Pricing Dashboard Act (Casey) - interactive dashboard with drug price and utilization data for federal programs
S. 773, Telehealth Innovation and Improvement Act (Gardner) - testing expanded coverage of telehealth services in Medicare
S. 988, Improving Transparency and Accuracy in Medicare Part D Spending Act (Capito) - payments on clean claims
H.R. 259, Medicaid Extenders Act (Pallone) - MFP demonstration, spousal impoverishment protections
H.R. 448, Medicare Drug Price Negotiation Act (Cummings) - Part D price negotiations, formulary changes
H.R. 789, Improving Transparency and Accuracy in Medicare Part D Spending Act (Welch) - payments on clean claims
H.R. 937, Right Rebate Act (Schrader) - Medicaid drug rebate program
H.R. 1034, Phair Pricing Act (Collins) - Part D rebates at the point of sale
H.R. 1035, Prescription Drug Price Transparency Act (Collins) - Medicare PBM standards
H.R. 1046, Medicare Negotiation and Competitive Licensing Act (Doggett) - Part D price negotiation
H.R. 1226, ACE Kids Act (Castor) - health homes for children with medically complex conditions
H.R. 1277, State Public Option Act (Lujan) - Medicaid buy-in option
H.R. 1301, Mental Health Telemedicine Expansion Act (DelBene) - Medicare coverage of mental health telehealth services
H.R. 1342, EMPOWER Care Act (Dingell) - MFP demonstration
H.R. 1343, Protecting Married Seniors from Impoverishment Act (Dingell) - spousal impoverishment protections
H.R. 1346, Medicare Buy-In and Health Care Stabilization Act (Higgins) - Medicare buy-in option
H.R. 1375, PAID Act (Kind) - transparency of Medicare secondary payer information
H.R. 1384, Medicare for All Act (Jayapal) - Medicare for All health care system
H.R. 1394, Medigap Consumer Protection Act (Doggett) - Medicare supplemental consumer protections
H.R. 1551, Quality Care for Moms and Babies Act (Engel) - quality measures in Medicaid and CHIP
H.R. 1781, Payment Commission Data Act (Carter) - MedPAC and MACPAC access to drug pricing and rebate data in Medicare and Medicaid
H.R. 1839, Medicaid Services Investment and Accountability Act (Ruiz) - MFP demonstration, spousal impoverishment protections, ACE Kids Act, Medicaid drug rebate program
Draft Medicare Advantage Quality Payment Relief Act (Kelly-Kind) - MA benchmark cap

Regulatory Issues:
Ongoing implementation issues for the Medicare Advantage (MA) and Medicare Part D prescription drug programs, including risk adjustment methodology, network adequacy and provider directories, encounter data and other data-related issues, and risk adjustment data validation (RADV) audit issues; bidding and payment issues (including MA rate assumptions, MA coding intensity, MA Secondary Payer issues, Part D reinsurance, Part D low income subsidies, Part D direct and indirect remuneration (DIR), and audits); calendar year 2020 policy and technical regulation for MA and Part D; MA and Part D proposed rule on drug pricing changes for 2020; CMSs price transparency proposal for direct-to-consumer advertisements; issues relating to 2019 Rate Notice and Call Letter; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); in-home health risk assessments; Medicare Medical Loss Ratio issues; implementation of sequestration under the Medicare Advantage and Part D programs; implications of the health insurer fee for MA and Part D plans; application process, audits to evaluate compliance with MA and Part D program rules, benefit design rules, enrollment rules, requirements for notice and denial forms, marketing materials review and approval, marketing activities, including conduct and compensation of brokers and agents and plan sponsor marketing staff; measurement and oversight of plan performance including Special Needs Plans (SNPs); quality measures, grievance and appeals processes, fraud and abuse compliance including training; contracting issues for Dual Eligible SNPs; Bipartisan Budget Act of 2018 changes to SNPs; Federal preemption of State authority under MA and Part D programs, Part D prescription drug event data reporting, Part D formulary rules, Part D pharmacy access standards, Part D coverage gap discount program, including employer group waiver plan (EGWP) issues, and other operational issues; issues raised by Part D coverage of new specialty drugs, the Part D non-interference policy and related issues (e.g., preferred pharmacy and any willing pharmacy requirements, standards for network pharmacy reimbursement, and policies regarding sponsor negotiation of pharmacy price concessions); CMS's proposed Part B drug demonstration program; Medication Therapy Management Program requirements and the Center for Medicare and Medicaid Innovation (CMMI) Demonstration; MA EGWP issues; CMMI's value-based insurance design (VBID) demonstration; Part D requirements for offering basic and enhanced alternative plans; MA and Part D systems issues affecting enrollment and disenrollment processing and payment and other operational issues; issues relating to MA and Part D Star Rating system including measures, the methodology for calculating ratings, and the role of the ratings for payment purposes; implementation of the Affordable Care Act (ACA) and the Bipartisan Budget Act of 2018 changes to the Part D coverage gap; functionality of the Medicare Personal Plan Finder and Drug Plan Finder; National Medicare Education Program; Medicare demonstration program on performance-based payments for physician groups; physician quality reporting initiative; issues relating to Medicare coverage policy and national coverage decisions; new payment system for physicians under MACRA, including implications for MA and Part D plans; Medicare clinical trials; Medicare/Medicaid integration for dual eligibles, including implementation of the Capitated Financial Alignment Demonstration and related issues (e.g., quality ratings); Medicaid managed care regulations and policies, including CMS's substantial revisions to the managed care regulations, mental health parity rules, the Medicaid managed care actuarial soundness standard, quality oversight, Medicaid and CHIP Payment and Access Commission (MACPAC), grievance and appeals processes, fraud and abuse compliance, beneficiary information requirements, treatment of Medicaid health plan member hospital days in the upper payment limit calculation; policies affecting State Medicaid funding, including block grants, the calculation of the federal medical assistance (federal matching) percentage (FMAP), and intergovernmental transfers (IGTs); coordination of benefits with state Medicaid programs; Medicaid prescription drug cost issues affecting Medicaid health plans including issues raised by Medicaid coverage of new specialty drugs; health plan-related Childrens Health Insurance Program (CHIP) issues, including eligibility and outreach issues and CHIP reauthorization; implementation of Medicaid changes made in Deficit Reduction Act of 2005, including Medicaid managed care organization provider tax issues; standards for electronic prescribing; implementation of Medicaid changes of interest to Medicaid health plans made in the ACA including Medicaid expansion, the managed care organization (MCO) prescription drug rebate provisions, minimum payments to primary care providers (PCPs), interactions between the Medicaid program and health insurance exchanges, and Medicaid and CHIP maintenance of effort (MOE) requirements; implications of the health insurer fee for Medicaid health plans; issues related to Medicaid Managed long-term care including home and community-based waiver services (HCBS); expanding the availability of Medicare Advantage and Medicaid health plan telemedicine programs; implications of the new non-discrimination rules for health plans participating in public programs; issues related to Medigap coverage; issues related to business continuity in relation to pandemics or natural events (e.g., hurricane, tornado, etc.); cybersecurity; provider directories; value-based insurance design models; issues relating to prescription drug price blueprint; Part D prescriber enrollment requirements; Part D recovery audit contractor programs; issues relating to enrollment of beneficiaries with ESRD into MA plans; issues related to health homes for children with medically complex conditions; socioeconomic status impacts on star ratings related to MA and Part D programs; and other issues relating to health care reform implementation.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code INS

16. Specific lobbying issues

S. 350, Competitive Health Insurance Reform Act (Daines) - McCarran-Ferguson Act
S. 455, Marketing and Outreach Restoration to Empower Health Education Act (Shaheen) - funding for outreach and education on ACA Exchanges
S. 466, Protecting Americans with Preexisting Conditions Act (Warner) - blocking updated Section 1332 guidance
S. 560, Ensuring Lasting Smiles Act (Baldwin) - coverage mandate for treatment of congenital anomaly or birth defect
S. 741, Cancer Drug Parity Act (Smith) -- cost sharing for oral anticancer drugs
S. 913, Disclosure of Price Information to Enrollees (Braun)
S. 961, Improving Health Insurance Affordability Act (Shaheen) - premium tax credits
S. 964, Marketplace Certainty Act (Shaheen) - cost-sharing subsidies
S. 967, Reducing Costs for Out-of-Network Services Act (Shaheen) - caps on out-of-network charges
S. 981, Medicare-X Choice Act (Bennet) - public option
H.R. 692, Pre-existing Conditions Protection Act (Walden) - pre-existing condition protections
H.R. 986, Protecting Americans with Preexisting Conditions Act (Kuster) - blocking updated Section 1332 guidance
H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act (Blunt Rochester) - funding for outreach and education on ACA Exchanges
H.R. 1010, Short-Term Plans (Castor) - blocking final rule that expands short-term plans
H.R. 1143, Educating Consumers on the Risks of Short-Term Plans Act (Eshoo) - standardized disclosures for short-term plans
H.R. 1379, Ensuring Lasting Smiles Act (Peterson) - coverage mandate for treatment of congenital anomaly or birth defect
H.R. 1385, State Allowance for a Variety of Exchanges Act (Kim) - funding for establishment of state-based Health Insurance Exchanges
H.R. 1386, Expand Navigators Resources for Outreach, Learning, and Longevity Act (Castor) - funding for Navigator Program
H.R. 1418, Competitive Health Insurance Reform Act (DeFazio) - McCarran-Ferguson Act
H.R. 1425, State Health Care Premium Reduction Act (Craig) - funding for state reinsurance programs
H.R. 1510, Premium Relief Act (Burgess) -- Patient and State Stability Fund
H.R. 1730, Cancer Drug Parity Act (Higgins) -- cost sharing for oral anticancer drugs
H.R. 1884, Protecting Pre-Existing Conditions and Making Health Care More Affordable Act (Pallone) - reinsurance funding, stabilization and affordability proposals
H.R. 2000, Medicare-X Choice Act (Delgado) - public option
H.R. 2061, Auto-Enrollment (Bera)

Regulatory Issues:
Insurance regulatory reform; issues related to the coordination of private and public disability income benefits; disability risk management; disability income insurance enrollment and awareness; issues related to encouraging impaired workers to stay in/return to the workforce; issues related to expanding long-term care insurance coverage; issues relating to the coordination of benefits between private health insurance plans and Medicaid; Medigap claims processing and crossover fees; Medigap cross-over claim issues, Medigap coverage, implementation of Medigap standardized plan offerings; Medigap carrier recoveries related to CMS fraud and abuse enforcement activities, and issues related to Medigap educational materials, and other Medigap issues; fraud and abuse issues affecting public and private insurance coverage; issues relating to antitrust; implementation of the Mental Health Parity Act requirements; implementation of the 21st Century Cures Act requirements; summary of benefits and coverage disclosures; pre-existing condition insurance plans; accountable care organizations; coverage of preventive services; preexisting condition exclusions; lifetime and annual dollar limits on benefits; patient protections; grandfathered health plan provisions; health reimbursement accounts; dependent coverage; treatment of expatriate plans; issues related to all payor claims databases; issues related to association health plans; issues related to fraud, waste, abuse, Stark/Anti-Kickback laws and regulations, non-discriminatory wellness programs; issues related to supplemental products; issues relating to dental coverage; issues relating to proposals for single-payer and Medicare/Medicaid buy-in options; issues related to implementation of the Telephone Consumer Protection Act; issues relating to third party payment of premiums; issues related to cost-sharing reductions (CSRs); issues related to interoperability and price transparency; issues relating to the individual market; and other issues relating to health care reform implementation.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Centers For Medicare and Medicaid Services (CMS), White House Office, Office of Management & Budget (OMB), Council of Economic Advisers (CEA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

S. 64, Preserve Access to Affordable Generics and Biosimilars Act (Grassley-Klobuchar) - prohibiting pay-for-delay settlements
S. 73, End Taxpayer Subsidies for Drug Ads Act (Shaheen) - prohibiting tax deduction for DTC advertising expenses
S. 102, Prescription Drug Price Relief Act (Sanders) - reforms linked to international pricing
S. 340, CREATES Act (Leahy) - removing barriers to generic drugs
S. 344, Hatch-Waxman Integrity Act (Tillis) - inter partes review process
S. 366, FLAT Prices Act (Durbin) - reforms for drugs with sudden price spikes
S. 378, Stop Price Gouging Act (Durbin) - excise tax for drugs that have price spikes
S. 474, SPIKE Act (Wyden) - justification for drug price increases
S. 476, Creating Transparency to Have Drug Rebates Unlocked Act (Wyden) - drug price transparency
S. 637, CURE High Drug Prices Act (Blumenthal) - remedies for price gouging
S. 657, Point of Sale Rebates (Braun)
S. 659, Biologic Patent Transparency Act (Collins) - patent disclosure requirements
S. 660, Efficiency and Transparency in Petitions Act (Braun) - FDA citizen petition process
S. 844, Short on Competition Act (Klobuchar) - remedies for marginally competitive drug markets
S. 977, Transparency Drug Pricing Act (Scott) - transparency and drug pricing reforms
H.R. 465, Prescription Drug Price Relief Act (Khanna) - reforms linked to international pricing
H.R. 938, BLOCKING Act (Schrader) - changes to 180-day period of market exclusivity for first generic applicant
H.R. 965, CREATES Act (Cicilline) - removing barriers to generic drugs
H.R. 985, FAST Generics Act (Welch) - removing barriers to generic drugs
H.R. 990, Hatch-Waxman Integrity Act (Flores) - inter partes review process
H.R. 1093, Stop Price Gouging Act (Pocan) - excise tax for drugs that have price spikes
H.R. 1188, FLAT Prices Act (Golden) - reforms for drugs with sudden price spikes
H.R. 1344, Competitive DRUGS Act (Doggett) - prohibiting pay-for-delay agreements
H.R. 1419, Public Option Deficit Reduction Act (DeFazio) - public option
H.R. 1499, Protecting Consumer Access to Generic Drugs Act (Rush) - prohibiting pay-for-delay agreements
H.R. 1503, Orange Book Transparency Act (Kelly) - removal of invalidated patents from Orange Book
H.R. 1506, FAIR Generics Act (Barragan) - changes to 180-day period of market exclusivity for first generic applicant
H.R. 1520, Purple Book Continuity Act (Eshoo) - access to updated information on biologics and biosimilars
H.R. 2038, State-Based, Market-Oriented Prescription Drug Negotiations Act (Meadows) - drug price negotiations
H.R. 2064, Sunshine for Samples Act (Chu) - reporting requirements on drug samples
H.R. 2069, SPIKE Act (Horsford) -justification for drug price increases
H.R. 2113, Prescription Drug STAR Act (Neal)-drug price transparency

Regulatory Issues:
Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Executive Office of the President (EOP)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

S. 12, Health Savings Act (Rubio) - HSA improvements
S. 80, Jobs and Premium Protection Act - (Barrasso) - health insurance tax
S. 172, Health Insurance Tax Relief Act (Gardner) - health insurance tax
S. 684, Middle Class Health Benefits Tax Repeal Act (Heinrich) - Cadillac tax on employer-provided coverage
H.R. 603, Health Savings Account Expansion Act (Gallagher) - HSA improvements
H.R. 748, Middle Class Health Benefits Tax Repeal Act (Courtney) - Cadillac tax on employer-provided coverage
H.R. 1398, Health Insurance Tax Relief Act (Bera) - health insurance tax

Regulatory Issues:
Annual insurer provider fees; issues concerning the patient-centered outcomes research fee; employer and individual coverage mandate; W-2 reporting requirements; health reimbursement accounts; deductibility limits for insurer compensation; health insurer and employer reporting of health coverage; issues related to implementation of health insurance tax; issues related to the refundable credit for coverage under a qualified health plan; issues related to coverage of chronic conditions in high deductible health plans; issues related to health savings accounts; issues related to the deductibility of employer-sponsored health coverage; issues related to enhancing tax treatment of long-term care insurance; issues related to qualified small employer health reimbursement accounts (QSEHRAs); issues related to implementation of the excise tax on high cost employer-sponsored health coverage; and other issues relating to health care reform implementation.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address: https://www.ahip.org/board-of-directors/

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes